Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Genentech Procures Amphora Oncology Program

  • Genentech reported that it will purchase Amphora's entire program for an unnamed early-stage oncology target with the potential to treat multiple oncology indications.

    The company thus acquired all the intellectual property for the program, including the preclinical lead and several backup series.

    “Amphora's drug discovery engine has produced and is continuing to produce extremely high quality new products,” points out C. Nicholas Hodge, Ph.D., Amphora's CSO and founder. “Amphora has shown that it is capable of moving programs quickly and cost-effectively from screening to proof-of-concept with surprisingly low attrition rates.”



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »